Nuclear factor-κ13 in development, prevention, and therapy of cancer

被引:254
作者
Van Waes, Carter
机构
[1] Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Bethesda, MD 20892 USA
[2] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
关键词
D O I
10.1158/1078-0432.CCR-06-2221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nuclear factor-kappa B (NF-kappa B) is a signal transcription factor that has emerged as an important modulator of altered gene programs and malignant phenotype in development of cancer. Major carcinogens and oncogenic viruses induce NF-kappa B activation, and a variety of subsequent oncogenic events contribute to a progressive increase in constitutive NF-kappa B activation as an important common pathway in most forms of cancer. NF-kappa B target genes promote tumor cell proliferation, survival, migration, inflammation, and angiogenesis. Inhibition of NF-kappa B has been found to be an important mechanism of action of steroids, nonsteroidal anti-inflammatory drugs, and natural and synthetic compounds that show therapeutic and preventive activity. Newer agents targeting the proteasome, inhibitor-kappa B kinase, and other upstream kinases involved in NF-kappa B activation have shown anticancer activity in clinical or preclinical studies.
引用
收藏
页码:1076 / 1082
页数:7
相关论文
共 100 条
  • [91] The putative oncoprotein Bcl-3 induces cyclin d1 to stimulate G1 transition
    Westerheide, SD
    Mayo, MW
    Anest, V
    Hanson, JL
    Baldwin, AS
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (24) : 8428 - 8436
  • [92] Wolf JS, 2001, CLIN CANCER RES, V7, P1812
  • [93] Defective IκBα in Hodgkin cell lines with constitutively active NF-κB
    Wood, KM
    Roff, M
    Hay, RT
    [J]. ONCOGENE, 1998, 16 (16) : 2131 - 2139
  • [94] Sulindac inhibits activation of the NF-κB pathway
    Yamamoto, Y
    Yin, MJ
    Lin, KM
    Gaynor, RB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (38) : 27307 - 27314
  • [95] Bortezomib (VELCADE®) in metastatic breast cancer:: pharmacodynamics, biological effects, and prediction of clinical benefits
    Yang, CH
    Gonzalez-Angulo, AM
    Reuben, JM
    Booser, DJ
    Pusztai, L
    Krishnamurthy, S
    Esseltine, D
    Stec, J
    Broglio, KR
    Islam, R
    Hortobagyi, GN
    Cristofanilli, M
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (05) : 813 - 817
  • [96] BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma:: Involvement of nuclear factor κB and mitochondria pathways
    Yang, JM
    Amiri, KI
    Burke, JR
    Schmid, JA
    Richmond, A
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (03) : 950 - 960
  • [97] Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells
    Yemelyanov, A
    Gasparian, A
    Lindholm, P
    Dang, L
    Pierce, JW
    Kisseljov, F
    Karseladze, A
    Budunova, I
    [J]. ONCOGENE, 2006, 25 (03) : 387 - 398
  • [98] The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
    Yin, MJ
    Yamamoto, Y
    Gaynor, RB
    [J]. NATURE, 1998, 396 (6706) : 77 - 80
  • [99] Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells
    Yu, Mng
    Yeh, Jason
    Van Waes, Carter
    [J]. CANCER RESEARCH, 2006, 66 (13) : 6722 - 6731
  • [100] NF-κB RelA poses epidermal proliferation riven by TNFR1 and JNK
    Zhang, JY
    Green, CL
    Tao, SY
    Khavari, PA
    [J]. GENES & DEVELOPMENT, 2004, 18 (01) : 17 - 22